Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure

Background: Pulmonary artery hypertension (PH), associated with increased left ventricular (LV) diastolic pressure and pulmonary vasoconstriction, is frequently observed in heart failure (HF), where it holds prognostic significance. We hypothesized that Cheyne-Stokes respiration (CSR) may contribute to increased pulmonary arterartery pressure (PAP) and right ventricular (RV) remodeling in HF, via hypoxia/hypercapnia cycles and adrenergic activation by the chemoreflex stimulation. Methods: Seventy-two HF patients(57 males, aged 65.1 SD 12.3 years, LV ejection fraction <50%, 33.2 SD 7.5%), on guideline recommended pharmacological/device treatment underwent thorough clinical, echocardiographic and neurohormonal assessment, 24-hour cardiorespiratory screening for arrhythmias and CSR, and chemoreflex test for hypoxic (HVR) and hypercapnic (HCVR) ventilatory responses. Results: Twenty patients (28%) showed significant CSR (24-hour apnea-hypopnea index, AHI >= 15). Patients with CSR presented with: a) higher systolic pulmonary artery pressure (sPAP: 42.8 standard deviation-SD 10.1 vs 32.3 SD 5.7 mmHg, p < 0.001), despite similar LV systolic and diastolic function; b) indexes of right chamber remodeling (all p < 0.05); c) enhanced HVR (median 0.78, interquartile range-IR 0.46-1.22 vs 0.42, IR 0.18-0.67 L/min/%, p = 0.01) and HCVR (1.17, IR 0.97-1.29 vs 0.72, IR 0.47-0.93 L/min/mmHg, p = 0.02); d) increased plasma norepinephrine levels (690, IR 477-868 vs 366, IR 226-508 ng/L, p < 0.001). Univariate predictors of sPAP > 35 mmHg were AHI, HVR, HCVR; only AHI maintained its predictive value at multivariate analysis (p = 0.017). Conclusions: CSR may contribute to increased pulmonary artery pressure and right chamber remodeling in HF, independently of the severity of LV systolic and diastolic dysfunction, likely via recurrent hypoxia/hypercapnia cycles and chemoreflex mediated adrenergic discharge. (C) 2015 Elsevier Ireland Ltd. All rights reserved.